Premium
High‐Mobility Group Box 1 Inhibition Alleviates Lupus‐Like Disease in BXSB Mice
Author(s) -
Zhang C.,
Li C.,
Jia S.,
Yao P.,
Yang Q.,
Zhang Y.
Publication year - 2014
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12165
Subject(s) - hmgb1 , systemic lupus erythematosus , proteinuria , proinflammatory cytokine , medicine , immune system , immunology , monoclonal antibody , lupus erythematosus , endocrinology , lupus nephritis , glomerulonephritis , antibody , pharmacology , disease , kidney , inflammation
High‐mobility group box 1 protein (HMGB1), a ubiquitous nuclear DNA‐binding protein, functions as a potent proinflammatory factor. In this study, we evaluated the effects of HMGB1 inhibition on murine lupus using the lupus‐prone model. We treated male BXSB mice with neutralizing anti‐HMGB1 monoclonal antibody (HMGB1 mA b) from age 16 weeks to 26 weeks. The control group received the same amount of control IgG. Lupus‐prone male BXSB mice treated with HMGB1mAb showed attenuated proteinuria, glomerulonephritis, circulating anti‐dsDNA and immune complex deposition. Levels of serum IL‐1 β , IL‐6, IL‐17 and IL‐18 were also significantly decreased by administration of HMGB1mAb in lupus‐prone BXSB mice. HMGB1mAb treatment also decreased the caspase‐1 activity in the kidneys of BXSB mice and reduced the mouse mortality. Our study supports that HMGB1 inhibition alleviates lupus‐like disease in BXSB mice and might be a potential treatment option for human SLE.